MGB Biopharma Limited

Industry Outlook

Puma Biotechnology, Inc. | March 16, 2023

Puma Biotechnology, Inc., a biopharmaceutical company, recently announced the online publication of the Phase II TBCRC041 randomized clinical trial results in JAMA Oncology. The trial investigated the use of alisertib, an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A, alone or in combination with fulvestrant in postmenopausal women with endocrine-resistant, HER2-negative metastatic breast cancer who were previously treated with fulvestrant. ...

AI

Viva Biotech, BioMap | May 11, 2021

The first generation of the China Biocomputing Conference, hosted by BioMap and Adock, was successfully launched in Suzhou. The conference's goal is to bring together biotech and IT industry partners to build a multi-party integrated industrial ecosystem and realize AI's full potential in the field of biotechnology. Viva Biotech was invited to the conference and announced a strategic alliance with BioMap. This alliance will combine BioMap's AI + biological computing en...

Industry Outlook

GlobeNewswire | October 03, 2023

Amicus Therapeutics a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone. As part of the collaboration, Blackstone Life Sciences and Blackstone Credit have agreed to...

Industrial Impact

Providence Therapeutics | July 13, 2022

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...